Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback